Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c‐Jun pathway in adaptive resistance to drug‐induced apoptosis
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Drugs that inhibit RAF/MEK signaling, such as vemurafenib, elicit profound but often temporary anti‐tumor responses in patients with BRAF V 600E melanoma. Adaptive responses to RAF/MEK inhibition occur on a timescale of hours to days, involve homeostatic responses that reactivate MAP kinase signaling and compensatory mitogenic pathways, and attenuate the anti‐tumor effects of RAF/MEK inhibitors. We profile adaptive responses across a panel of melanoma cell lines using multiplex biochemical measurement, single‐cell assays, and statistical modeling and show that adaptation involves at least six signaling cascades that act to reduce drug potency (IC 50 ) and maximal effect (i.e., E max ≪ 1). Among these cascades, we identify a role for JNK/c‐Jun signaling in vemurafenib adaptation and show that RAF and JNK inhibitors synergize in cell killing. This arises because JNK inhibition prevents a subset of cells in a cycling population from becoming quiescent upon vemurafenib treatment, thereby reducing drug E max . Our findings demonstrate the breadth and diversity of adaptive responses to RAF/MEK inhibition and a means to identify which steps in a signaling cascade are most predictive of phenotypic response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Data-driven modeling reveals signaling correlates of BRAF-mutant melanoma cellular response to RAF/MEK inhibition Overview of the systematic measurements using single-cell phenotypic and multiplex biochemical assays to profile signaling biochemistry and cell state in 10 BRAFV600E/D melanoma cell lines exposed to four RAF inhibitors and one MEK inhibitor at multiple doses and times. Multiplex single-cell immunofluorescence assays were used in the follow-up experiments on selected cell lines for treatments with vemurafenib, JNK-IN-8, and their combination. Dose–response curves representing 72-h viability measurements for six selected BRAFV600E melanoma cell lines after treatment with vemurafenib. Ranges of estimated IC50 and Emax for the selected lines are shown. Data are represented as mean ± SD. Pairwise distribution and correlation of estimated IC50 and Emax values for responses (72-h viability) of 8 cell lines to four RAF inhibitors and one MEK inhibitor. Each dot represents one drug/cell line combination. Sensitive cell lines are arbitrarily defined based on their IC50s (the most widely used metric for evaluation of drug response; log10[IC50] < −6.5). Cell line-specific model calibration for two selected cell lines C32 and WM115. Left: R2, Q2, and MSPE for C32 and WM115 models built with increasing numbers of PLSR components. Middle: Relative viability as measured experimentally (z-score-scaled) or as predicted by the three-component PLSR models using tenfold cross-validation. R2 reports model fit, and Q2 reports model prediction accuracy. Right: PLSR score plots for the first two components of C32 and WM115 models. Shown PLSR models were developed using RPPA data from Supplementary Dataset S3. PLSR loading plots for the first two components of C32 and WM115 models. Source data are available online for this figure.](https://figures.cochat.ai/paper-figures/b579f60ae84b4e3ca9fbe8346f715fc7/systematic-analysis-of-brafv600e-melanomas-reveals-a-role-for-jnk-cjun-pathway-figure-1.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This is consistent with BRAFV600E melanoma studies that demonstrated a role for the JNK/c-Jun signaling pathway in vemurafenib adaptation and resistance to drug-induced apoptosis [55].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The BRAFV600E oncoprotein constitutively activates pro-mitogenic RAF/MEK/ERK signaling (Davies et al, 2002; Fecher et al, 2008), and therapy with RAF inhibitors such as vemurafenib (Zelboraf ; PLX4032) causes tumor regression in many patients (Bollag et al, 2010; Chapman et al, 2011; Flaherty et…”
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 2×
“For 25 BRAFV600E melanoma lines in the Cancer Cell Line Encyclopedia (Barretina et al, 2012), we also observed a statistically significant correlation between JUN expression levels and PLX4720 sensitivity Molecular Systems Biology 11: 797 | 2015 ª 2015 The Authors (Spearman’s q = 0.47, P = 0.02; see below; Supplementa…”
InfluentialImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 6×
“…potential biomarkers. pS6 has been proposed as a clinical biomarker for assessing the effectiveness of targeted therapy in BRAFV600E tumors (Corcoran et al, 2013), and our data add the insight that c-Jun up-regulation can also be estimated by measuring pS6 levels. pS6 levels are a…”
InfluentialPartial least-squares regression: a tutorial
Geladi, P., & Kowalski, B. R. (1986) · Analytica Chimica Acta · doi:10.1016/0003-2670(86)80028-9 · Cited by 6,992 · cited 2×
“We used partial least squares regression (PLSR) modeling (Geladi & Kowalski, 1986; Janes & Yaffe, 2006) to identify statistically significant covariation between molecular signals (input data; measured by RPPA) and corresponding cellular responses (output data; relative viability and apoptotic…”
The Ki-67 protein: From the known and the unknown
Scholzen, T., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9 · Cited by 4,646 · cited 1×
“…protein on Ser807/811, a modification that promotes cell cycle progression and is present during the S/G2/M phases of the cell cycle, and the levels of nuclear Ki-67, a marker of proliferation that scores negative only in quiescent cells (Buchkovich et al, 1989; Scholzen & Gerdes, 2000).”
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103 · cited 1×
“However, the duration of response is variable and relapse to lethal drug-resistant disease is common (Flaherty et al, 2010).”
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810 · cited 1×
“…activates pro-mitogenic RAF/MEK/ERK signaling (Davies et al, 2002; Fecher et al, 2008), and therapy with RAF inhibitors such as vemurafenib (Zelboraf ; PLX4032) causes tumor regression in many patients (Bollag et al, 2010; Chapman et al, 2011; Flaherty et al, 2012; Sosman et al, 2012).”
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“Seven of the tested cell lines have been genetically characterized through the Cancer Genome Project (Garnett et al, 2012) (Supplementary Dataset S1).”
Self-citationBendall, S. C., Simonds, E. F., Qiu, P., Amir, E.-A. D., Krutzik, P. O., Finck, R., Bruggner, R. V., Melamed, R., Trejo, A., Ornatsky, O. I., et al. (2011) · Science · doi:10.1126/science.1198704 · Cited by 2,279 · cited 1×
“In principle, it may be advantageous to use high-multiplicity single-cell imaging for primary data collection (Bendall et al, 2011; Gerdes et al, 2013).”
Cited by
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method
Lin, J.-R., Fallahi-Sichani, M., & Sorger, P. K. (2015) · Nature Communications · doi:10.1038/ncomms9390 · Cited by 562
“…the application of CycIF to drug response at a single-cell level and show that multiplex single-cell measurement reveals new aspects of drug sensitivity and resistance 22,23 ; further refinement of the method will be reported at our web site at http://lincs.hms.harvard.edu/lin-NatCommun-2015.”
Self-citationThe JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer
Hammouda, M., Ford, A., Liu, Y., & Zhang, J. (2020) · Cells · doi:10.3390/cells9040857 · Cited by 284
Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 235
“To score viability and apoptosis, we used a dyebased imaging assay: The cell-permeable DNA dye Hoechst 33342 was used to mark nuclei, and DEVD-NucView488 caspase-3 substrate was used to mark apoptosis, as previously described in detail (Fallahi-Sichani et al, 2015).”
InfluentialSelf-citationMiller, M. A., Oudin, M. J., Sullivan, R. J., Wang, S. J., Meyer, A. S., Im, H., Frederick, D. T., Tadros, J., Griffith, L. G., Lee, H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0933 · Cited by 166
Ramsdale, R., Jorissen, R. N., Li, F. Z., Al-Obaidi, S., Ward, T., Sheppard, K. E., Bukczynska, P. E., Young, R. J., Boyle, S. E., Shackleton, M., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab1111 · Cited by 143
Zhang, J., Späth, S. S., Marjani, S. L., Zhang, W., & Pan, X. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby007 · Cited by 154
Gerosa, L., Chidley, C., Fröhlich, F., Sanchez, G., Lim, S. K., Muhlich, J., Chen, J.-Y., Vallabhaneni, S., Baker, G. J., Schapiro, D., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.10.002 · Cited by 110
“, 2019), or dependence on specific survival pathways (Coppé et al., 2019; Fallahi-Sichani et al., 2015; Hangauer et al., 2017).”
BackgroundSelf-citationSu, Y., Ko, M. E., Cheng, H., Zhu, R., Xue, M., Wang, J., Lee, J. W., Frankiw, L., Xu, A., Wong, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15956-9 · Cited by 101
Niepel, M., Hafner, M., Duan, Q., Wang, Z., Paull, E. O., Chung, M., Lu, X., Stuart, J. M., Golub, T. R., Subramanian, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01383-w · Cited by 97
Self-citationLeveraging Transcriptional Dynamics to Improve BRAF Inhibitor Responses in Melanoma
Smalley, I., Kim, E., Li, J., Spence, P., Wyatt, C. J., Eroglu, Z., Sondak, V. K., Messina, J. L., Babacan, N. A., Maria–Engler, S. S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.023 · Cited by 99
Gong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0048-0 · Cited by 92
Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
Pizzimenti, S., Ribero, S., Cucci, M. A., Grattarola, M., Monge, C., Dianzani, C., Barrera, G., & Muzio, G. (2021) · Antioxidants · doi:10.3390/antiox10121942 · Cited by 79
HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy
Emmons, M. F., Faião-Flores, F., Sharma, R., Thapa, R., Messina, J. L., Becker, J. C., Schadendorf, D., Seto, E., Sondak, V. K., Koomen, J. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0040 · Cited by 73
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
Titz, B., Lomova, A., Le, A., Hugo, W., Kong, X., ten Hoeve, J., Friedman, M., Shi, H., Moriceau, G., Song, C., et al. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.28 · Cited by 72
Functional random forest with applications in dose-response predictions
Rahman, R., Dhruba, S. R., Ghosh, S., & Pal, R. (2019) · Scientific Reports · doi:10.1038/s41598-018-38231-w · Cited by 63
AP-1 transcription factor network explains diverse patterns of cellular plasticity in melanoma cells
Comandante-Lou, N., Baumann, D. G., & Fallahi‐Sichani, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111147 · Cited by 60
Self-citationA biomaterial screening approach reveals microenvironmental mechanisms of drug resistance
Schwartz, A. D., Barney, L. E., Jansen, L., Nguyen, T. V., Hall, C. L., Meyer, A. S., & Peyton, S. R. (2017) · Integrative Biology · doi:10.1039/c7ib00128b · Cited by 54
Ortiz, M. V., Kobos, R., Walsh, M. F., Slotkin, E. K., Roberts, S. S., Berger, M. F., Hameed, M., Solit, D. B., Ladanyi, M., Shukla, N. N., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26002 · Cited by 49
Seip, K., Fleten, K. G., Barkovskaya, A., Nygaard, V., Haugen, M. H., Engesæter, B. Ø., Mælandsmo, G. M., & Prasmickaite, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7671 · Cited by 41
Zou, Y., Xiong, J.-B., Ma, K., Wang, A., & Qian, K. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.074 · Cited by 42
Kaus, A. S., & Sareen, D. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00448 · Cited by 45
“…this approach is likely to reveal a wealth of new findings is supported by a line of previous LINCS studies in areas of cell lineage identity, genome modification and cancer research (Duan et al., 2014; Gujral et al., 2014; Ma’ayan and Duan, 2014; Olson et al., 2014; Fallahi-Sichani et al., 2015).”
ResultNew era of integrated cancer biomarker discovery using reverse-phase protein arrays
Nishizuka, S., & Mills, G. B. (2015) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2015.11.009 · Cited by 41
Ebelt, N. D., Kaoud, T. S., Edupuganti, R., Ravenstein, S. X. V., Dalby, K. N., & Berg, C. L. V. D. (2017) · Oncotarget · doi:10.18632/oncotarget.20581 · Cited by 43
Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
Khaliq, M., & Fallahi‐Sichani, M. (2019) · Cancers · doi:10.3390/cancers11101480 · Cited by 43
Self-citationMALT1 promotes melanoma progression through JNK/c-Jun signaling
Wang, Y., Zhang, G.-H., Jin, J. Y., Degan, S., Tameze, Y., & Zhang, J. Y. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.68 · Cited by 32
Recent advances in microfluidics for single-cell functional proteomics
Gebreyesus, S. T., Muneer, G., Huang, C., Siyal, A. A., Anand, M., Chen, Y., & Tu, H. (2023) · Lab on a Chip · doi:10.1039/d2lc01096h · Cited by 38
JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21
Colleoni, B., Paternot, S., Pita, J. M. G., Bisteau, X., Coulonval, K., Davis, R. J., Raspé, E., & Roger, P. P. (2017) · Oncogene · doi:10.1038/onc.2017.7 · Cited by 35
Jones, D. S., Jenney, A., Joughin, B. A., Sorger, P. K., & Lauffenburger, D. A. (2018) · Science Signaling · doi:10.1126/scisignal.aal1601 · Cited by 30
Self-citationLü, Y., Ng, A. H. C., Chow, F. E., Everson, R. G., Helmink, B. A., Tetzlaff, M. T., Thakur, R., Wargo, J. A., Cloughesy, T. F., Prins, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24293-4 · Cited by 30
Kani, K., Garri, C., Tiemann, K., Malihi, P. D., Punj, V., Nguyen, A. L., Lee, J. S., Hughes, L. D., Alvarez, R. M., Wood, D. M., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0564 · Cited by 27
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers
Jansen, R. A., Mainardi, S., Dias, M. H., Bosma, A. R., van Dijk, E., Selig, R., Albrecht, W., Laufer, S., Zender, L., & Bernards, R. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2319492121 · Cited by 26
JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2–Targeted Therapies
Manole, S., Richards, E. J., & Meyer, A. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0123 · Cited by 25
“For example, surviving melanoma cells after Raf/Mek inhibitor treatment are enriched for higher JNK activation, and Raf/JNK dual inhibitor treatment is synergistic (25).”
Epigenetic modulation reveals differentiation state specificity of oncogene addiction
Khaliq, M., Manikkam, M., Martínez, E. D., & Fallahi‐Sichani, M. (2021) · Nature Communications · doi:10.1038/s41467-021-21784-2 · Cited by 29
Self-citationEvaluating the consistency of large-scale pharmacogenomic studies
Rahman, R., Dhruba, S. R., Matlock, K., Niz, C. D., Ghosh, S., & Pal, R. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby046 · Cited by 23
Kessler, B. E., Mishall, K. M., Kellett, M. D., Clark, E. G., Pugazhenthi, U., Pozdeyev, N. V., Kim, J., Tan, A. C., & Schweppe, R. E. (2018) · Oncogene · doi:10.1038/s41388-018-0617-1 · Cited by 20
Haugh, A. M., Salama, A. K. S., & Johnson, D. B. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.09.005 · Cited by 20
JNK2 Is Required for the Tumorigenic Properties of Melanoma Cells
Du, L., Anderson, A., Nguyen, K. T., Ojeda, S. S., Ortiz-Rivera, I., Nguyen, T., Zhang, T., Kaoud, T. S., Gray, N. S., Dalby, K. N., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00083 · Cited by 19
Self-citationRoller, D. G., Capaldo, B. J., Bekiranov, S., Mackey, A. J., Conaway, M. R., Petricoin, E. F., Gioeli, D. G., & Weber, M. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6548 · Cited by 19
Tanimura, K., Yamada, T., Horinaka, M., Katayama, Y., Fukui, S., Morimoto, K., Nakano, T., Tokuda, S., Morimoto, Y., Iwasaku, M., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.018 · Cited by 20
Computational models of melanoma
Albrecht, M., Lucarelli, P., Kulms, D., & Sauter, T. (2020) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-020-00126-7 · Cited by 21
“21 phosphoproteins were measured over time in a panel of 10 cell lines subjected to different doses of five different RAF/MAP2K inhibitors [37].”
BackgroundMethodRožanc, J., Sakellaropoulos, T., Antoranz, A., Guttà, C., Podder, B., Vetma, V., Rufo, N., Agostinis, P., Pliaka, V., Sauter, T., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0210-8 · Cited by 17
Long non-coding RNA FENDRR inhibits migration and invasion of cutaneous malignant melanoma cells
Chen, X., Chen, P., Chen, S., Jin Wei, L. U., Ma, T., Shi, G., & Sheng, L. (2020) · Bioscience Reports · doi:10.1042/bsr20191194 · Cited by 16
RetractedTobeigei, F. H., Gahtani, R. M., Shaikh, A. A., Ali, A. A., Kameli, N., Kamli, H. M., & Rajagopalan, P. (2021) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.025187 · Cited by 17
Comandante-Lou, N., Khaliq, M., Venkat, D., Manikkam, M., & Fallahi‐Sichani, M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007688 · Cited by 17
“A more efficacious drug or drug combination engages a larger proportion of cells [21,22].”
BackgroundResultInfluentialSelf-citationThe cancer cell proteome and transcriptome predicts sensitivity to targeted and cytotoxic drugs
Rydenfelt, M., Wongchenko, M. J., Klinger, B., Yan, Y., & Blüthgen, N. (2019) · Life Science Alliance · doi:10.26508/lsa.201900445 · Cited by 17
Gong, K., Guo, G., Beckley, N. A., Yang, X., Zhang, Y., Gerber, D. E., Minna, J. D., Burma, S., Zhao, D., Akbay, E. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27276-7 · Cited by 16
Zhu, E. Y., Riordan, J. D., Vanneste, M., Henry, M. D., Stipp, C. S., & Dupuy, A. J. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00310-7 · Cited by 14
Localized immune surveillance of primary melanoma in the skin deciphered through executable modeling
Howell, R. S. M., Davies, J., Clarke, M. A., Appios, A., Mesquita, I., Jayal, Y., Ringham-Terry, B., del Río, I. B., Fisher, J., & Bennett, C. L. (2023) · Science Advances · doi:10.1126/sciadv.add1992 · Cited by 15
Lim, H. N., Jang, J., Shin, H. J., Jang, J., Ahn, J. S., & Jang, J. (2020) · Molecules · doi:10.3390/molecules25081974 · Cited by 14
Su, Y., Liu, C., Lu, X., Li, G., Shao, S., Kong, Y., Lee, J. W., Ng, R. H., Wong, S. K., Robert, L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/724740 · Cited by 12
Kot, M., Simiczyjew, A., Wądzyńska, J., Ziętek, M., Matkowski, R., & Nowak, D. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01788-3 · Cited by 14
Dissecting Pathway Disturbances Using Network Topology and Multi-platform Genomics Data
Zhang, Y., Linder, M. H., Shojaie, A., Ouyang, Z., Shen, R., Baggerly, K., Baladandayuthapani, V., & Zhao, H. (2017) · Statistics in Biosciences · doi:10.1007/s12561-017-9193-0 · Cited by 10
“Recent advances of cancer research in melanoma indicate that the BRAF pathway has one of the most prevalent genetic changes in the development and progression of melanoma [3].”
BackgroundCytoskeletal Remodelling as an Achilles’ Heel for Therapy Resistance in Melanoma
Barreno, A., & Orgaz, J. L. (2022) · Cells · doi:10.3390/cells11030518 · Cited by 9
Chen, X., Ye, Q., Srivastava, P., & Al-Kuwari, N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.361516 · Cited by 11
Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas
Vachtenheim, J., & Ondrušová, Ľ. (2021) · Life · doi:10.3390/life11050424 · Cited by 10
Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
Abecunas, C., Whitehead, C. E., Ziemke, E. K., Baumann, D. G., Frankowski-McGregor, C. L., Sebolt, J. S., & Fallahi‐Sichani, M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0883 · Cited by 9
Self-citationBian, Y., Shan, G., Bi, G., Xu, Z., Liang, J., Yan, Y., Guo, W., Sui, Q., Yi, Y., Shi, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65441-4 · Cited by 17
Ruffini, F., Ceci, C., Atzori, M. G., Caporali, S., Levati, L., Bonmassar, L., Cappellini, G. C. A., D’Atri, S., Graziani, G., & Lacal, P. M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106782 · Cited by 9
“JNK/c-Jun pathway is an important regulator of cell proliferation, metabolism and death, and both transcription factors have been involved in vemurafenib resistance [61,62].”
Seip, K., Jørgensen, K., Haselager, M. V., Albrecht, M., Haugen, M. H., Egeland, E. V., Lucarelli, P., Engebraaten, O., Sauter, T., Mælandsmo, G. M., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.023 · Cited by 8
Reproducibility and Crossplatform Validation of Reverse-Phase Protein Array Data
Byron, A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9755-5_10 · Cited by 8
Hartung, N., Huynh, C. T.-K., Gaudy‐Marqueste, C., Flavian, A., Malissen, N., Richard, M. A., Hubert, F., & Grob, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176080 · Cited by 8
Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer
Rubio-Cuesta, B., Carretero-Puche, C., Llamas, P., Sarmentero, J., Gil-Calderon, B., Lens-Pardo, A., Antón-Pascual, B., Rubio-González, E., Cámara-Jurado, M., Salamanca, J., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03058-6 · Cited by 7
BRAF V600E ‐PROTAC versus inhibitors in melanoma cells: Deep transcriptomic characterization
Alhassan, S., Elmageed, Z. Y. A., Errami, Y., Wang, G., Abi‐Rached, J., Kandil, E. H., & Zerfaoui, M. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70251 · Cited by 8
Kumar, V., Sabaté-Cadenas, X., Soni, I., Stern, E., Vias, C., Ginsberg, D., Mateo, C. R., Pulido, R., Dodel, M., Mardakheh, F. K., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03021-4 · Cited by 7
Recursive model for dose-time responses in pharmacological studies
Dhruba, S. R., Rahman, A., Rahman, R., Ghosh, S., & Pal, R. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2831-4 · Cited by 6
Khoshkenar, P., Lowry, E., & Mitchell, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-94941-8 · Cited by 9
Phenotype switching in highly invasive resistant to vemurafenib and cobimetinib melanoma cells
Simiczyjew, A., Kot, M., Majkowski, M., Ziętek, M., Matkowski, R., & Nowak, D. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02452-0 · Cited by 6
The JNK Pathway in Drug Resistance
Hu, L., Zou, F., Grandis, J. R., & Johnson, D. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813753-6.00004-4 · Cited by 5
Euxanthone Impairs the Metastatic Potential of Osteosarcoma by Reducing COX‐2 Expression
Chen, X., Deng, M., Zhou, X., Wang, X., Ye, Y., Zhu, J., Jiang, H., Chen, X., & Zha, W. (2018) · The Anatomical Record · doi:10.1002/ar.23992 · Cited by 5
“…regulators which are significantly involved in melanoma development and metastasis (Kovary and Bravo, 1991; Shaulian and Karin, 2001), both c-jun and cfos have been identified as the major regulating proteins in AP-1 protein family in melanoma (Oliva et al., 2007; Fallahi-Sichani et al., 2015).”
BackgroundRetractedRobust latent-variable interpretation of in vivo regression models by nested resampling
Caulk, A. W., & Janes, K. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-55796-2 · Cited by 5
“417 5) Update independent condition scores, t, by projecting X onto w, 418 t = Xw (4) 419 6) Calculate variable and time weights for the dependent data, q, by back projecting the 420 residual of the Y matrix onto t, 421 q = YTt (5) 422”
Taking out the JNK: A window of opportunity to improve cancer therapy
Ferrao, P. T. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1128515 · Cited by 5
“The JNK-JUN pathway has been verified as a key pathway in mediating survival following BRAF and MEK inhibitor treatment in parallel studies by other research groups.(3,4) The JNK signaling pathway”
ResultAn investigation of proteomic data for application in precision medicine
Matlock, K., Dhruba, S. R., Nazir, M., & Pal, R. (2018) · IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI ...) · doi:10.1109/bhi.2018.8333447 · Cited by 4
“The second dataset measured the viability and apoptosis in the same cell lines using Fluorescence imaging apoptosis assay [4].”
BackgroundMethodInfluentialKim, J., & Schoeberl, B. (2015) · Science Signaling · doi:10.1126/scisignal.aad4989 · Cited by 4
Reverse Phase Protein Arrays for Compound Profiling
Moerke, N. J., & Fallahi‐Sichani, M. (2016) · Current Protocols in Chemical Biology · doi:10.1002/cpch.9 · Cited by 3
“This protocol describes a method for preparation of lysates from cells treated with drugs or tool compounds that is suitable for preparation of RPPAs, which was used in a study of BRAF kinase inhibitors in human melanoma cell lines (Fallahi-Sichani et al., 2015).”
MethodSelf-citationA Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition
Sammons, R. M., & Dalby, K. N. (2020) · Springer eBooks · doi:10.1007/978-3-030-48283-1_6 · Cited by 3
Models of Cancer Drug Discovery and Response to Therapy
Comandante-Lou, N., & Fallahi‐Sichani, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11356-x · Cited by 2
Self-citationLiu, W., Zhang, X., Liang, X., Guo, Y., Zhou, Z., Zhu, S., Peng, C., & Chen, X. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08090-1 · Cited by 2
A Biomaterial Screening Approach Reveals Microenvironmental Mechanisms of Drug ResistancePreprint
Schwartz, A. D., Barney, L. E., Jansen, L., Nguyen, T. V., Hall, C. L., Meyer, A. S., & Peyton, S. R. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/168039 · Cited by 1
Barker, C. G., Sharma, S., Santos, A. M., Nikolakopoulos, K.-S., Velentzas, A. D., Völlmy, F., Minia, A., Pliaka, V., Altelaar, M. A. F., Wright, G. J., et al. (2024) · Qeios · doi:10.1101/2024.12.05.626952 · Cited by 1
Degefu, Y. N., Bujnowska, M., Baumann, D. G., & Fallahi‐Sichani, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.06.686987 · Cited by 1
Self-citationInvestigating the Mechanism of MenaINV-Driven Metastasis
Oudin, M. J. (2016)
Other Positions and Employment
Niepel, M., & Kreuzaler, F. M. (2015)
Self-citationMinimal models of invasion and clonal selection in cancerPreprint
Paterson, C. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2005.09592 · Cited by 1
“JNK1 is a signalling protein which is associated with stress and inflammation, interacts with several distinct signalling pathways, and there are results suggesting that activation of JNK1 is associated with drug resistance and conversely that inhibition of JNK1 is associated with reversal of resistance [131, 132].”
BackgroundTargeted Therapies for BRAF-Mutant Metastatic Melanoma
Johnson, D. B., Dummer, R., Flaherty, K. T., & Smalley, K. S. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-46029-1_40-1
Developing statistical and bioinformatic analysis of genomic data from tumours
Thakur, R. (2018) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Su, Y.-P., Li, G., Ko, M. E., Cheng, H.-J., Zhu, R.-H., Xue, M., Wang, J. K., Lee, J., Frankiw, L. S., Xu, A. M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/767988
Targeted Therapies for BRAF-Mutant Metastatic Melanoma
Johnson, D. B., Dummer, R., Flaherty, K. T., & Smalley, K. S. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_40
Cancer cells survival is dependent on the lincRNA JUNIPreprint
Kumar, V., Sabaté-Cadenas, X., Soni, I., Stern, E., Vias, C., Ginsberg, D., Dodel, M., Mardakheh, F. K., Shkumatava, A., & Shaulian, E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.21.496924
Kumar, V., Sabaté-Cadenas, X., Soni, I., Stern, E., Vias, C., Ginsberg, D., Mateo, C. R., Pulido, R., Dodel, M., Mardakheh, F. K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.23.563579
Nabi, N., Shafat, P. M., Bashir, S., & Khan, M. S. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_2
Ammar, U. M., El‐Din, M. M. G., Abdel‐Maksoud, M. S., Ali, E., El–Gamal, M. I., Mahmoud, Z., Ahn, S., Nguyen, N. H. A., Kim, E., Park, J., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145699 · Cited by 1
Additional file 1 of Computational models of melanoma
Albrecht, M., Lucarelli, P., Kulms, D., & Sauter, T. (2020) · Figshare · doi:10.6084/m9.figshare.12307859
Kot, M., Simiczyjew, A., Wądzyńska, J., Ziętek, M., Matkowski, R., & Nowak, D. (2024) · Figshare · doi:10.6084/m9.figshare.26942661
Kot, M., Simiczyjew, A., Wądzyńska, J., Ziętek, M., Matkowski, R., & Nowak, D. (2024) · Figshare · doi:10.6084/m9.figshare.26942664
Barker, C. G., Sharma, S., Santos, A. M., Nikolakopoulos, K.-S., Velentzas, A. D., Garcia, C. T., Sharma, A., Völlmy, F., Minia, A., Pliaka, V., et al. (2026) · Molecular Systems Biology · doi:10.1038/s44320-025-00183-5 · Cited by 1
Rôle de c-Jun dans la réponse aux inhibiteurs de la voie des MAPK dans les mélanomes
Pohorecka, M. (2018) · theses.fr (ABES) · doi:10.70675/4cf7db7bz9142z4de8zbcbbzd5860991d571
Degefu, Y. N., Bujnowska, M., Baumann, D. G., & Fallahi‐Sichani, M. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117965 · Cited by 1
Self-citationClosing the adaptive window: immune–metabolic strategies to constrain melanoma therapy resistance
Riccardo, F., Conti, L., Defilippi, P., Arina, P., Audrito, V., & Calautti, E. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1954638
Metadata
- Authors
- Fallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Sorger, Peter K
- Venue
- Molecular Systems Biology
- Published
- 2015-03-01
- Volume
- 11
- Issue
- 3
- Pages
- 797-797
- ISSN
- 1744-4292 (ISSN-L)
- PMC
- PMC4380931
- OpenAlex
- W2110682642
- Cited by
- 99
- References
- 68
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 8 · 2020: 14 · 2019: 12 · 2018: 12 · 2017: 11 · 2016: 8 · 2015: 7
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 25 d)
- Locations
- Molecular Systems Biology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- NIH LINCS Program (U54HG006097, U54HL127365, CA139980, CA130876)
- Merck Fellow of the Life Sciences Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BRAF V600E melanoma, vemurafenib, adaptive drug resistance, JNK/c-Jun signaling, MAPK signaling, drug synergy, cell cycle quiescence, melanoma cell lines, Emax, IC50, compensatory signaling pathways
- MeSH terms
- Vemurafenib, Cell Survival, Drug Synergism, Humans, Indoles, Melanoma, Mutation, Sulfonamides, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.